SCHEMBL1552227

SCHEMBL1552227

N#C/C(=C\C=C\c1ccc(O)c(O)c1)C(=O)OCc1ccccc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 6/20 0.69
AKR1B10 O60218 1/20 0.58
TTR P02766 1/20 0.58
AKR1B1 P15121 1/20 0.58
ALDH1A1 P00352 2/20 0.55
MAPT P10636 2/20 0.55
RECQL P46063 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
TDP1 Q9NUW8 2/20 0.55
DNM1 Q05193 3/20 0.53
EGFR P00533 2/20 0.50
ERBB2 P04626 2/20 0.50
EEF2K O00418 1/20 0.50
PLK4 O00444 1/20 0.50
PIM1 P11309 1/20 0.50
AXL P30530 1/20 0.50
MAPKAPK2 P49137 1/20 0.50
GSK3A P49840 1/20 0.50
GSK3B P49841 1/20 0.50
IRAK1 P51617 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1552561 1.00 MAOB (0.69) MAOBAKR1B10TTRAKR1B1ALDH1A1
SCHEMBL1552825 0.88 MAOB (0.63) MAOBTTRALDH1A1MAPTGSK3B
SCHEMBL1552823 0.88 MAOB (0.63) MAOBTTRALDH1A1MAPTGSK3B
SCHEMBL1551530 0.81 MAOB (0.60) MAOBALDH1A1MAPTSMN1; SMN2EGFR
SCHEMBL1551528 0.81 MAOB (0.60) MAOBALDH1A1MAPTSMN1; SMN2EGFR
Ls-104 SCHEMBL3956490 0.80 MAOB (1.00) MAOBALDH1A1MAPTRECQLSMN1; SMN2
Ls-104 SCHEMBL3956495 0.80 MAOB (1.00) MAOBALDH1A1MAPTRECQLSMN1; SMN2
SCHEMBL13678405 0.79 MAOB (0.62) MAOBTTRALDH1A1MAPTRECQL
SCHEMBL6915091 0.79 MAOB (0.68) MAOBAKR1B10TTRAKR1B1ALDH1A1
SCHEMBL6915100 0.79 MAOB (0.68) MAOBAKR1B10TTRAKR1B1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1467967-B1 COMPOUNDS FOR MODULATING CELL PROLIFERATION HOSPITAL FOR SICK CHILDREN (CA) 2011-04-27 EP claimed
US-7563820-B2 Compounds for modulating cell proliferation THE HOSPITAL FOR SICK CHILDREN (CA) 2009-07-21 US claimed
US-20070197660-A1 Compounds for modulating cell proliferation THE HOSPITAL FOR SICK CHILDREN (CA) 2007-08-23 US claimed
EP-1654220-A4 COMPOUNDS FOR MODULATING CELL PROLIFERATION HOSPITAL FOR SICK CHILDREN (CA) 2006-10-25 EP claimed
EP-1654220-A1 COMPOUNDS FOR MODULATING CELL PROLIFERATION The Hospital for Sick Children (CA) 2006-05-10 EP claimed
US-20050085538-A1 Compounds for modulating cell proliferation HOSPITAL FOR SICK CHILDREN, THE (CA) 2005-04-21 US claimed
WO-2005012234-A1 COMPOUNDS FOR MODULATING CELL PROLIFERATION THE HOSPITAL FOR SICK CHILDREN (CA) 2005-02-10 WO claimed
EP-1467967-A1 COMPOUNDS FOR MODULATING CELL PROLIFERATION The Hospital for Sick Children (CA) 2004-10-20 EP claimed
WO-2003062190-A1 COMPOUNDS FOR MODULATING CELL PROLIFERATION THE HOSPITAL FOR SICK CHILDREN (CA) 2003-07-31 WO claimed
EP-1467967-B1 COMPOUNDS FOR MODULATING CELL PROLIFERATION HOSPITAL FOR SICK CHILDREN (CA) 2011-04-27 EP disclosed
EP-1467967-B1 COMPOUNDS FOR MODULATING CELL PROLIFERATION HOSPITAL FOR SICK CHILDREN (CA) 2011-04-27 EP disclosed
US-7563820-B2 Compounds for modulating cell proliferation THE HOSPITAL FOR SICK CHILDREN (CA) 2009-07-21 US disclosed
US-7563820-B2 Compounds for modulating cell proliferation THE HOSPITAL FOR SICK CHILDREN (CA) 2009-07-21 US disclosed
US-7563820-B2 Compounds for modulating cell proliferation THE HOSPITAL FOR SICK CHILDREN (CA) 2009-07-21 US disclosed
EP-1551381-A2 STYRYLACRYLONITRILE COMPOUNDS FOR INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR The Hospital for Sick Children (CA) 2005-07-13 EP disclosed
US-20050085538-A1 Compounds for modulating cell proliferation HOSPITAL FOR SICK CHILDREN, THE (CA) 2005-04-21 US disclosed
WO-2005012234-A1 COMPOUNDS FOR MODULATING CELL PROLIFERATION THE HOSPITAL FOR SICK CHILDREN (CA) 2005-02-10 WO disclosed
EP-1467967-A1 COMPOUNDS FOR MODULATING CELL PROLIFERATION The Hospital for Sick Children (CA) 2004-10-20 EP disclosed
WO-2004032911-A2 STYRYLACRYLONITRILE COMPOUNDS FOR INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR THE HOSPITAL FOR SICK CHILDREN (CA) 2004-04-22 WO disclosed
WO-2003062190-A1 COMPOUNDS FOR MODULATING CELL PROLIFERATION THE HOSPITAL FOR SICK CHILDREN (CA) 2003-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050085538-A1 Compounds for modulating cell proliferation CCNO, CCNY, CCND3 MAOB 1268/4885AKR1B10 592/4885TTR 4684/4885
US-20070197660-A1 Compounds for modulating cell proliferation CCND3, CCNO, WNT3 MAOB 2008/4885AKR1B10 790/4885TTR 4432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.